Last updated: September 9, 2026
Telithromycin, marketed as Ketek by Aventis and later Sanofi, is a commercial case study in how safety restrictions can erase the value of a differentiated anti-infective. The FDA approved telithromycin in 2004 for community-acquired bacterial pneumonia, acute bacterial exacerbations of chronic bronchitis, and acute bacterial sinusitis. Hepatotoxicity, syncope, visual disturbances, and drug-interaction concerns led to a boxed warning, withdrawal of two U.S. indications, severe-use restrictions, and eventual U.S. market discontinuation. Its patent-based commercial opportunity has expired, and current revenue exposure is negligible.
What is the FDA regulatory status of telithromycin?
Telithromycin is no longer a commercially significant U.S. product. The FDA approved NDA 21-144 on April 1, 2004, under the brand name Ketek. The original label covered three respiratory infections:
| Regulatory milestone |
Date |
Commercial effect |
| FDA approval of Ketek |
April 1, 2004 |
U.S. launch for three respiratory indications |
| FDA safety communication and label changes |
February 2006 |
Acute sinusitis and chronic bronchitis indications removed |
| Boxed warning added |
February 2006 |
Severe hepatotoxicity and syncope warnings |
| Restricted indication |
2006 onward |
Use limited primarily to community-acquired bacterial pneumonia |
| U.S. commercial discontinuation |
By the late 2010s |
No meaningful U.S. branded market remained |
The FDA determined that the risks of serious liver injury outweighed the benefits for acute bacterial sinusitis and acute bacterial exacerbations of chronic bronchitis. The community-acquired bacterial pneumonia indication remained because the disease can be more serious and the treatment alternatives differ by patient and pathogen profile.[1]
The approved U.S. dose was 800 mg once daily for seven to 10 days. The label warned against use in patients with myasthenia gravis, a neuromuscular disorder in which telithromycin could worsen weakness and respiratory failure. It also identified clinically relevant CYP3A4-mediated interactions, including concerns involving simvastatin, lovastatin, and certain antiarrhythmic agents.[2]
When did telithromycin lose exclusivity?
Telithromycin’s principal U.S. compound patent expired in the mid-2010s, eliminating the core patent barrier to generic competition. The product’s economic exclusivity ended earlier in practical terms because regulatory restrictions and safety concerns sharply reduced demand.
What patents protected Ketek?
The telithromycin estate included composition-of-matter, pharmaceutical composition, manufacturing, and use-related intellectual property. Public patent records identify the following representative U.S. patents and patent families:
| Patent or family |
General subject matter |
Commercial relevance |
| U.S. Patent No. 5,635,485 |
Ketolide compounds, including telithromycin-related chemistry |
Core composition protection |
| Follow-on formulation and process families |
Solid forms, preparation, purification, and pharmaceutical compositions |
Potential technical barriers after core compound expiry |
| Method-of-use patents |
Treatment of susceptible respiratory infections |
Narrower protection, vulnerable to non-infringing labels |
The core composition patent’s term was approximately 20 years from the relevant U.S. filing date, subject to patent-term adjustment or extension. Public patent databases place expiration in the 2014 period for the principal U.S. compound protection. Any later patents would not have restored the economic value of the original franchise because the product’s safety profile had already impaired prescribing.
The Orange Book historically listed telithromycin patents associated with NDA 21-144. Current Orange Book listings and marketing status should be distinguished from historical patent protection: a product may retain archived patent records even after the sponsor has stopped commercial distribution.
How did telithromycin’s safety profile affect market dynamics?
Safety risk changed telithromycin from a broad respiratory anti-infective into a restricted reserve option. The key commercial damage occurred in four areas:
- Physicians reduced prescribing after reports of acute liver failure and deaths.
- The FDA removed two of the three original indications.
- Payers and hospital systems had little incentive to select a higher-risk product when alternative macrolides, fluoroquinolones, and beta-lactam combinations were available.
- Generic entry became less attractive because the remaining addressable market was small and clinically constrained.
The FDA’s 2006 action followed reports of serious hepatic injury, including liver transplantation and death. The agency also identified loss of consciousness and visual disturbances as clinically important adverse reactions.[1]
The risk-benefit profile was especially difficult for outpatient respiratory infections. Telithromycin offered activity against certain macrolide-resistant respiratory pathogens, but that advantage did not offset the safety issues for routine sinusitis and bronchitis. The product therefore lost the high-volume indications that had supported its original commercial thesis.
What was telithromycin’s financial trajectory?
Telithromycin’s financial trajectory had three stages: pre-launch investment, early commercial growth, and rapid value destruction after the safety intervention.
Pre-launch and early launch phase
Aventis developed telithromycin as the first marketed ketolide, positioning it against macrolide-resistant respiratory pathogens. The product was expected to capture use in community-acquired respiratory infections where resistance limited older macrolides.
The launch opportunity was broad because the initial U.S. label covered three common respiratory indications. European commercialization preceded or accompanied the U.S. launch, creating a multinational revenue opportunity under the Aventis and Sanofi platforms.
Post-warning contraction
The 2006 label restrictions removed the largest volume opportunities. The brand retained a narrower pneumonia indication, but pneumonia prescribing was more concentrated in hospital and specialist settings. The product could no longer compete as a routine primary-care antibiotic.
The safety event also damaged sales productivity. Sales force investment, physician education, pharmacovigilance, and legal costs became less supportable against a declining prescription base. The product’s expected lifecycle shifted from a potential major respiratory franchise to a limited, declining asset.
Mature and post-commercial phase
Sanofi’s later public reporting generally did not disclose telithromycin as a material standalone revenue contributor. That reporting treatment is consistent with a product that had fallen below the threshold for separate financial disclosure. The commercial value after the regulatory restrictions was primarily residual revenue from limited prescriptions, not an active growth platform.
No reliable current revenue base exists for telithromycin as a major marketed pharmaceutical. Any remaining sales would be geographically limited, dependent on local authorization and supply, and immaterial relative to Sanofi’s broader portfolio.
What is the Orange Book status of telithromycin?
The historical U.S. Orange Book record is relevant to generic-entry analysis, but it does not indicate a current commercial contest comparable to an active branded product.
A generic applicant would historically have evaluated:
- Paragraph I certification if no relevant patent information was listed.
- Paragraph II certification if a listed patent had already expired.
- Paragraph III certification if approval was sought after the patent expiration date.
- Paragraph IV certification if the applicant asserted that a listed patent was invalid or would not be infringed.
Because telithromycin’s principal patent protection expired years ago, a new Paragraph IV strategy would have limited commercial significance unless a currently enforceable formulation, process, or use patent created a separate barrier. The more important obstacle is market economics: a generic entrant would face a small, safety-sensitive market with uncertain prescriber demand.
Which companies challenged or competed with telithromycin?
Telithromycin competed against established respiratory anti-infectives rather than against a single direct substitute.
| Competitor class |
Representative products |
Competitive effect |
| Macrolides |
Azithromycin, clarithromycin |
Lower safety and prescribing friction in routine respiratory infections |
| Respiratory fluoroquinolones |
Levofloxacin, moxifloxacin |
Broad activity and established pneumonia use |
| Beta-lactams |
Amoxicillin/clavulanate, cephalosporins |
Standard treatment options for several respiratory indications |
| Other anti-infectives |
Doxycycline and pathogen-directed therapies |
Lower-cost alternatives in selected patients |
Generic versions of azithromycin, clarithromycin, levofloxacin, and amoxicillin/clavulanate created substantial price pressure. Telithromycin’s premium positioning depended on clinical differentiation, but its adverse-event profile weakened that differentiation.
No major biosimilar risk applies. Telithromycin is a small-molecule antibiotic, not a biologic. The relevant competitive threat is generic substitution and therapeutic substitution.
What patent litigation affected telithromycin?
The major commercial legal exposure was linked to safety disclosures, product liability, and regulatory compliance rather than a sustained patent litigation campaign.
The product’s litigation and enforcement risk included:
- Claims involving severe liver injury and other adverse events.
- Allegations concerning the adequacy and timing of safety disclosures.
- Regulatory scrutiny over clinical-trial data and adverse-event reporting.
- Potential product-liability settlements and defense costs.
- Generic patent litigation risk before core patent expiry.
The regulatory controversy reduced the value of any patent litigation victory. Even if Sanofi had preserved additional years of exclusivity, the restricted indication and damaged physician confidence would have limited incremental sales.
What formulation patents protected telithromycin?
Formulation and process patents could cover the active pharmaceutical ingredient in tablets, excipient combinations, solid-state properties, particle characteristics, or manufacturing steps. These rights would have been narrower than the composition patent and more vulnerable to design-around strategies.
A generic applicant could potentially avoid a formulation claim by changing:
- Excipient selection.
- Tablet manufacturing method.
- Particle-size distribution.
- Crystalline or amorphous form.
- Coating composition.
- Manufacturing sequence or purification conditions.
The commercial importance of such patents declines sharply when the active ingredient is old, the indication is restricted, and the product has low prescription volume.
How strong is the telithromycin patent estate?
Telithromycin’s historical patent estate was technically meaningful but commercially weak by the time safety restrictions took effect.
| Strength factor |
Assessment |
| Core composition protection |
Strong during the protected term |
| Follow-on formulation protection |
Potentially moderate, but narrower and design-around vulnerable |
| Method-of-use protection |
Limited by label scope and induced-infringement risk |
| Regulatory exclusivity |
Expired |
| Patent life remaining |
None of commercial significance |
| Generic-entry deterrence today |
Low |
| Manufacturing barriers |
Possible process complexity, but unlikely to prevent generic development |
| Market value of enforcement |
Low because demand is restricted |
Telithromycin’s chemistry may require specialized synthesis and purification, but manufacturing complexity alone does not create durable exclusivity. A generic manufacturer can justify process development only if expected volume and pricing support the investment.
What generic launch scenarios exist for telithromycin?
Three scenarios describe the remaining generic opportunity.
Scenario 1: No meaningful U.S. generic launch
This is the most commercially rational outcome if U.S. branded distribution has ended and the remaining addressable market is minimal. FDA approval would not guarantee meaningful sales.
Scenario 2: Limited hospital or specialist generic supply
A manufacturer could pursue a small-volume product for community-acquired bacterial pneumonia or selected resistant infections. The launch would likely rely on contract manufacturing and minimal commercial infrastructure.
Scenario 3: Non-U.S. market continuation
Telithromycin may remain authorized or available in selected jurisdictions under local regulatory conditions. Such markets could support niche sales, but fragmented registration, pharmacovigilance obligations, and safety restrictions would limit scale.
A label strategy based on a narrow indication could reduce infringement risk for method-of-use patents, but it would also reduce the market available to the generic product.
How does telithromycin compare with other macrolide antibiotics?
Telithromycin had a theoretical efficacy advantage against some macrolide-resistant organisms because ketolide chemistry was designed to improve ribosomal binding. Its commercial disadvantage was the safety profile.
| Factor |
Telithromycin |
Azithromycin |
Clarithromycin |
| Drug class |
Ketolide |
Macrolide azalide |
Macrolide |
| Main historical use |
Community-acquired pneumonia |
Broad respiratory and other infections |
Respiratory and selected other infections |
| Generic availability |
Available only as a limited legacy opportunity |
Broad |
Broad |
| Major commercial issue |
Hepatotoxicity and restricted use |
Resistance and QT concerns |
Drug interactions and resistance |
| Current market position |
Negligible |
Established generic market |
Established generic market |
| Biosimilar risk |
None |
None |
None |
Telithromycin’s clinical differentiation was insufficient to overcome the safety and commercial advantages of established generic alternatives.
What licensing deals affected telithromycin?
Aventis was the principal developer and commercial sponsor before the company’s 2004 merger with Sanofi-Synthélabo created Sanofi-Aventis, later Sanofi. The commercial transition was therefore primarily corporate consolidation rather than a later high-value out-licensing transaction.
No major current licensing transaction is associated with telithromycin. Its asset value declined after the FDA safety action, reducing the rationale for regional licensing, co-promotion, or acquisition by another large pharmaceutical company.
What is the geographic coverage of telithromycin protection?
Telithromycin patent protection was pursued across major pharmaceutical markets, including the United States and Europe. Geographic coverage depended on national validation, prosecution outcomes, patent-term rules, and regulatory authorization.
The market experienced geographic divergence:
- The United States imposed major label restrictions after the safety review.
- European authorities also restricted use and reviewed the product’s benefit-risk profile.
- Individual countries could retain, suspend, or discontinue authorization under national implementation procedures.
- Patent expiry did not produce a uniform commercial outcome because regulatory availability varied by jurisdiction.
The product’s geographic footprint therefore became fragmented. Patent coverage in a country had little value if the corresponding marketing authorization was suspended or the product was no longer supplied.
What revenue exposure remains for telithromycin?
Current direct revenue exposure is negligible relative to Sanofi’s operating portfolio. Telithromycin is not a material driver of Sanofi revenue, earnings, pipeline value, or valuation.
The more relevant financial exposures are historical:
- Lost sales from the withdrawal of sinusitis and bronchitis indications.
- Reduced return on clinical-development and launch investment.
- Product-liability and legal-defense costs.
- Pharmacovigilance and regulatory-compliance expenses.
- Lost opportunity to build a major ketolide franchise.
- Lower value of related commercial infrastructure and manufacturing capacity.
The asset is best classified as a discontinued or legacy anti-infective, not as a current growth or licensing opportunity.
Key Takeaways
- Telithromycin was FDA-approved in 2004 as Ketek for three respiratory indications.
- The FDA removed two indications and added a boxed warning in 2006 because of severe hepatotoxicity and other safety risks.
- The product retained a narrow community-acquired pneumonia indication but lost broad primary-care demand.
- The principal composition patent expired in the mid-2010s, ending meaningful patent-based exclusivity.
- No biosimilar risk applies because telithromycin is a small molecule.
- Generic-entry risk is legally high but commercially low because the market is restricted and demand is limited.
- Telithromycin has no material current revenue exposure for Sanofi.
- The drug’s commercial history demonstrates that regulatory safety action can destroy franchise value before patent expiry.
FAQs About Telithromycin Patent and Market Risk
Is telithromycin still approved by the FDA?
The product was FDA-approved, but Ketek is no longer a material marketed U.S. product. Historical FDA approval should not be confused with current commercial availability.
What caused Ketek sales to decline?
Serious liver injury, syncope, visual disturbances, drug interactions, and the 2006 removal of two indications caused the decline.
Can a generic company still launch telithromycin?
A generic company could pursue approval if applicable regulatory and manufacturing requirements are met, but the commercial opportunity is small and the product has no meaningful remaining composition-patent barrier.
Does telithromycin have pediatric exclusivity?
No commercially relevant current pediatric exclusivity remains. Any historical regulatory exclusivity would have expired long ago.
Is telithromycin a viable licensing asset?
Telithromycin is generally not a viable large-scale licensing asset. Potential value would be limited to niche geographic supply, legacy authorization, or specialized anti-infective markets.
References
- U.S. Food and Drug Administration. (2006). FDA public health advisory: Ketek (telithromycin).
- U.S. Food and Drug Administration. (2013). Ketek (telithromycin) prescribing information.
- U.S. Food and Drug Administration. (2024). Drugs@FDA: Ketek, NDA 21-144.
- European Medicines Agency. (2007). European Medicines Agency recommends restricting the use of Ketek.
- U.S. Patent and Trademark Office. (1997). U.S. Patent No. 5,635,485: Ketolide compounds.
- Sanofi. (2004-2010). Annual reports and financial statements.
